Peapack Gladstone Financial Corp Boosts Stake in Novo Nordisk A/S (NYSE:NVO)

Peapack Gladstone Financial Corp boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 17.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,156 shares of the company’s stock after acquiring an additional 4,122 shares during the period. Peapack Gladstone Financial Corp’s holdings in Novo Nordisk A/S were worth $3,353,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Envestnet Asset Management Inc. grew its position in shares of Novo Nordisk A/S by 1.4% in the second quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company’s stock valued at $607,242,000 after purchasing an additional 58,935 shares in the last quarter. Raymond James & Associates boosted its stake in Novo Nordisk A/S by 1.0% during the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after buying an additional 36,223 shares during the last quarter. Natixis Advisors LLC grew its holdings in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares in the last quarter. International Assets Investment Management LLC increased its stake in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares during the last quarter. Finally, DSM Capital Partners LLC raised its holdings in shares of Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after acquiring an additional 1,593,303 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Friday. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus price target of $150.40.

Novo Nordisk A/S Stock Down 1.5 %

NYSE:NVO opened at $106.95 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $479.94 billion, a price-to-earnings ratio of 34.61, a price-to-earnings-growth ratio of 1.43 and a beta of 0.40. Novo Nordisk A/S has a 52 week low of $96.53 and a 52 week high of $148.15. The stock’s fifty day moving average is $110.59 and its two-hundred day moving average is $126.22.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.